Cutaneous Melanoma

P2, N=29, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

P2, N=29, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: May 2026 --> May 2031

Our study provides a spatially resolved blueprint of the melanoma TME and identifies CORO1A as a functional regulator within the immune niche, where its modulation enhances T-cell activity and synergizes with ICB. These findings reveal spatial organization as a critical determinant of immunotherapy efficacy and nominate CORO1A as a promising target for combination therapy.

Furthermore, the combination of vemurafenib with cysmethynil, a proof-of-concept ICMT inhibitor, showed efficacy in combating RAC1P29S-driven resistance of BRAFV600E melanoma cells in both in vitro and in vivo settings...We further validated the role of TAZ in RAC1P29S-driven resistance by demonstrating that introducing a constitutively-active TAZ mutant enhanced the resistance to MAPK pathway inhibitors in native cells, phenocopying the effect of RAC1P29S. The novel application of MAPK pathway inhibitors and cysmethynil combination in RAC1P29S-driven MAPK-pathway-inhibitor-resistant melanoma cells extends the potential utility of ICMT inhibitors, and also provides a new mechanism for targeting ICMT in cancer.

P=N/A, N=40, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting

P3, N=790, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Jun 2027 --> Nov 2026

The i31-SLNB more accurately stratifies patients under consideration for SLNB into groups based on risk of SLN positivity than the clinicopathologic-only MIA nomogram.

Tumor-intrinsic NLRC5 promotes vasculature that is permissive to infiltration by antitumor immune cells. In addition to upregulating MHC-I, NLRC5 may enhance alternative antigen-processing pathways and attenuate autophagic degradation of MHC-I, thereby augmenting tumor immunogenicity.

In a subcutaneous melanoma model, the vaccine suppressed tumor growth, prolonged survival, and remodeled the tumor microenvironment by increasing effector cell infiltration and reducing immunosuppressive regulatory T cells. This work presents a rationally designed bacterial vaccine platform for targeted cancer immunotherapy.

P=N/A, N=500, Recruiting, Mayo Clinic | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2028

Compared with partial responders, complete responders showed enrichment of FABP4 and reduced expression of cancer markers. Microwave therapy produced local tumor responses and associated inflammatory transcriptomic changes in complete responders, supporting further clinical evaluation in cutaneous melanoma metastases.

CuB is a potential candidate for combination with chemotherapeutics or immune checkpoint inhibitors, offering a novel melanoma treatment strategy.